A cohort study of over 300 adults either diagnosed with mpox between May 2022 to January 2023 (post-MPX) or who were at risk but never infected (no-MPX) found that more than half of those diagnosed with mpox during the 2022 outbreak still had lingering physical effects 11 to 18 months later. Most reported appearance-related changes, and some continued to experience anorectal or urinary problems. The study is published in Annals of Internal Medicine.
Continue Reading this article here
